Chinese Startup Gestala Raises $21 Million to Pioneer Non-Invasive Brain Technology
Beijing, Sunday, 15 March 2026.
Securing $21.6 million just two months after launch, Chinese startup Gestala is pioneering non-invasive ultrasound brain technology, challenging surgical implants and signaling a major shift in global neurotechnology.
A Non-Invasive Leap in Neurotechnology
Barely two months after its launch in mid-January 2026, Gestala has secured CN¥150 million—approximately $21.6 million to $21.7 million—in an oversubscribed angel funding round [1][2][3]. Described as the largest angel round in China’s brain-computer interface (BCI) sector, the investment values the nascent firm between $100 million and $200 million [1][5]. The round was co-led by Guosheng Capital and Dalton Venture, with participation from several other prominent backers, including Tsing Song Capital and Gobi Partners [1][2]. Notably, investor commitments for the round exceeded $58 million, underscoring strong market interest in alternative neurotechnology applications [1].
Accelerated Timelines and Manufacturing
Fueled by this capital injection, Gestala—founded by serial entrepreneur and former NeuroXess executive Phoenix Peng—is executing an aggressive expansion strategy [2][5]. The company plans to dedicate the funds to research and development, alongside constructing a dedicated manufacturing facility in China [1][5]. This operational scaling includes expanding its specialized engineering team from 15 to 35 employees, representing a workforce increase of 133.333 percent by the end of 2026 [1][5].
The Expanding Global BCI Race
Gestala’s rapid ascent highlights the intensifying global competition within the neurotechnology sector. China’s domestic BCI ecosystem is maturing quickly; rival firm Neuracle recently secured the country’s first NMPA approval for an implantable BCI designed to restore motor function, while another startup, StairMed, has raised a combined 120 million across its recent funding rounds [4]. These entities are increasingly positioning themselves against a formidable roster of U.S.-based developers, including Precision Neuroscience, Science Corp, Synchron, and the OpenAI-backed Merge Labs [4].